Display options
Cite
Nakamura M, Sasai N, Hisatome I, et al. Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clin Pharmacol. 2014;6:79-86doi: 10.2147/CPAA.S61462.
Nakamura, M., Sasai, N., Hisatome, I., & Ichida, K. (2014). Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clinical pharmacology : advances and applications, 679-86. https://doi.org/10.2147/CPAA.S61462
Nakamura, Makiko, et al. "Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes." Clinical pharmacology : advances and applications vol. 6 (2014): 79-86. doi: https://doi.org/10.2147/CPAA.S61462
Nakamura M, Sasai N, Hisatome I, Ichida K. Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. Clin Pharmacol. 2014 May 03;6:79-86. doi: 10.2147/CPAA.S61462. eCollection 2014. PMID: 24833923; PMCID: PMC4014383.
Copy Download .nbib Format: NLM
Share it on

Clin Pharmacol. 2014 May 03;6:79-86. doi: 10.2147/CPAA.S61462. eCollection 2014.

Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes.

Clinical pharmacology : advances and applications

Makiko Nakamura, Nobuo Sasai, Ichiro Hisatome, Kimiyoshi Ichida

Affiliations

  1. Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
  2. Sasai Clinic, Kanagawa, Japan.
  3. Division of Regenerative Medicine and Therapeutics, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Sciences, Tottori University, Tottori, Japan.

PMID: 24833923 PMCID: PMC4014383 DOI: 10.2147/CPAA.S61462

Abstract

BACKGROUND: Hyperuricemia has been proposed to be a risk factor for cardiovascular disease and chronic kidney disease. Since diabetes is often complicated by hypertension and hyperuricemia, efficient therapeutic strategy against these two complications is very important in diabetic treatment. It has been reported that the antihypertensive drug, irbesartan, inhibits the renal uric acid reabsorptive transporters, URAT1 and GLUT9; this result suggests that irbesartan decreases serum uric acid level (SUA).

SUBJECTS AND METHODS: A retrospective study of 107 patients with hypertension and diabetes was performed to analyze the effects of irbesartan on blood pressure, estimated glomerular filtration rate (eGFR), and SUA. The follow-up period was 6-12 months. Seventy percent of the patients were diagnosed with diabetic nephropathy stage II-IV. We excluded patients treated with drugs that influenced SUA. The multiple logistic regression analysis was introduced to identify the relative factors for SUA decline. The time-dependent SUA changes were examined in a mixed-linear model.

RESULTS: Irbesartan reduced blood pressure significantly after 1, 6, and 12 months' treatment. No subject showed significant change in eGFR from baseline level throughout the period. The multiple logistic regression analysis revealed that SUA baseline significantly influenced SUA decline after 6-12 months. In patients whose SUA baseline was ≥5.9 mg/dL, the SUA was significantly decreased from 6.6±0.16 mg/dL to 6.2±0.16 mg/dL (P=0.010), after 12 months' irbesartan treatment. In the SUA baseline <5.9 mg/dL group, the SUA did not show significant change over the monitoring period.

CONCLUSION: Our results demonstrate that irbesartan reduces the risk of hyperuricemia. No decline in renal function was observed after the initiation of irbesartan treatment. The present report determines the criteria of SUA baseline for introducing an antihyperuricemic effect using irbesartan. Its antihypertensive effect coupled with SUA decline would be effective for the treatment of hypertension complicated by hyperuricemia.

Keywords: angiotensin-receptor blocker; diabetes; hypertension; hyperuricemia; serum uric acid

References

  1. Nutr Metab Cardiovasc Dis. 2013 Aug;23(8):707-14 - PubMed
  2. BMJ. 2012 Jan 12;344:d8190 - PubMed
  3. J Hum Hypertens. 2006 Jan;20(1):45-50 - PubMed
  4. Am J Hum Genet. 2008 Dec;83(6):744-51 - PubMed
  5. Am J Physiol Regul Integr Comp Physiol. 2000 Jul;279(1):R1-8 - PubMed
  6. Nature. 2002 May 23;417(6887):447-52 - PubMed
  7. J Cardiovasc Pharmacol. 1996 Aug;28(2):259-63 - PubMed
  8. J Am Soc Nephrol. 2010 Jan;21(1):64-72 - PubMed
  9. J Pharmacol Sci. 2010;114(1):115-8 - PubMed
  10. J Am Soc Nephrol. 2004 Jan;15(1):164-73 - PubMed
  11. Ann Intern Med. 1980 Dec;93(6):817-21 - PubMed
  12. Cardiovasc Diabetol. 2007 Sep 29;6:26 - PubMed
  13. Nefrologia. 2008;28(1):56-60 - PubMed
  14. PLoS One. 2013 Nov 12;8(11):e76827 - PubMed
  15. J Rheumatol. 2000 Jun;27(6):1501-5 - PubMed
  16. Cardiovasc Diabetol. 2012 May 17;11:53 - PubMed
  17. Cardiovasc Diabetol. 2013 Nov 04;12:159 - PubMed
  18. Clin Exp Nephrol. 2014 Aug;18(4):613-20 - PubMed
  19. Am J Hypertens. 2008 Oct;21(10):1157-62 - PubMed
  20. J Biol Chem. 2008 Oct 3;283(40):26834-8 - PubMed
  21. PLoS One. 2011;6(11):e27817 - PubMed

Publication Types